Skip to main content
Search
Main content

Publications

Our scientific output and findings

From groundbreaking discoveries in basic science to innovative clinical insights, our publications showcase the breadth and depth of research taking place at the UK DRI. 

Nature
Published
Capillary pericytes regulate cerebral blood flow in health and disease.
Authors
Catherine N Hall, Clare Reynell, Bodil Gesslein, Nicola B Hamilton, Anusha Mishra, Brad A Sutherland, Fergus M O'Farrell, Alastair M Buchan, Martin Lauritzen, David Attwell
Capillary pericytes regulate cerebral blood flow in health and disease.
Nature
Published
Capillary pericytes regulate cerebral blood flow in health and disease.
Authors
Catherine N Hall, Clare Reynell, Bodil Gesslein, Nicola B Hamilton, Anusha Mishra, Brad A Sutherland, Fergus M O'Farrell, Alastair M Buchan, Martin Lauritzen, David Attwell
Capillary pericytes regulate cerebral blood flow in health and disease.
N Engl J Med
Published
Thrombotic microangiopathy associated with interferon beta.
Authors
David Hunt, David Kavanagh, Iain Drummond, Belinda Weller, Chris Bellamy, James Overell, Stephen Evans, Andrew Jackson, Siddharthan Chandran
Thrombotic microangiopathy associated with interferon beta.
N Engl J Med
Published
Thrombotic microangiopathy associated with interferon beta.
Authors
David Hunt, David Kavanagh, Iain Drummond, Belinda Weller, Chris Bellamy, James Overell, Stephen Evans, Andrew Jackson, Siddharthan Chandran
Thrombotic microangiopathy associated with interferon beta.
N Engl J Med
Published
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Authors
Stephen Salloway, Reisa Sperling, Nick C Fox, Kaj Blennow, William Klunk, Murray Raskind, Marwan Sabbagh, Lawrence S Honig, Anton P Porsteinsson, Steven Ferris, Marcel Reichert, Nzeera Ketter, Bijan Nejadnik, Volkmar Guenzler, Maja Miloslavsky, Daniel Wang, Yuan Lu, Julia Lull, Iulia Cristina Tudor, Enchi Liu, Michael Grundman, Eric Yuen, Ronald Black, H Robert Brashear,
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.